Different Influences of Statin Treatment in Preventing At-Risk Stroke Subtypes: A Post Hoc Analysis of J-STARS-Reference-Cited by-同舟云学术

Different Influences of Statin Treatment in Preventing At-Risk Stroke Subtypes: A Post Hoc Analysis of J-STARS

Published:2020-05-01 Issue:5 Volume:27 Page:449-460
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Hosomi Naohisa¹,Kitagawa Kazuo²,Nagai Yoji³,Nakagawa Yoko⁴,Aoki Shiro¹,Nezu Tomohisa¹,Kagimura Tatsuo⁴,Maruyama Hirofumi¹,Origasa Hideki⁵,Minematsu Kazuo⁶,Uchiyama Shinichiro⁷,Matsumoto Masayasu¹⁸,

Affiliation:

1. Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences

2. Department of Neurology, Tokyo Women's Medical University School of Medicine

3. Center for Clinical Research, Kobe University Hospital

4. Division of Medical Statistics, Translational Research Center for Medical Innovation, Foundation for Biomedical Research and Innovation at Kobe

5. Division of Biostatistics and Clinical Epidemiology, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences

6. National Cerebral and Cardiovascular Center

7. Clinical Research Center, International University of Health and Welfare, Center for Brain and Cerebral Vessels, Sanno Hospital and Sanno Medical Center

8. Sakai City Medical Center, Sakai City Hospital Organization

Publisher

Japan Atherosclerosis Society

Subject

Biochemistry, medical,Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/jat/27/5/27_50518/_pdf

Reference17 articles.

1. 1) Amarenco P, Goldstein LB, Szarek M, Sillesen H, Rudolph AE, Callahan A, 3rd, Hennerici M, Simunovic L, Zivin JA, Welch KM and Investigators S: Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke, 2007; 38: 3198-3204

2. 2) Sillesen H, Amarenco P, Hennerici MG, Callahan A, Goldstein LB, Zivin J, Messig M, Welch KM and Stroke Prevention by Aggressive Reduction in Cholesterol Levels I: Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke, 2008; 39: 3297-3302

3. 3) Amarenco P, Benavente O, Goldstein LB, Callahan A, 3rd, Sillesen H, Hennerici MG, Gilbert S, Rudolph AE, Simunovic L, Zivin JA and Welch KM: Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke, 2009; 40: 1405-1409

4. 4) Kitagawa K, Hosomi N, Nagai Y, Kagimura T, Ohtsuki T, Maruyama H, Origasa H, Minematsu K, Uchiyama S, Nakamura M, Matsumoto M and J-STARS collaborators: Cumulative effects of LDL cholesterol and CRP levels on recurrent stroke and TIA. J Atheroscler Thromb, 2018 in press;

5. 5) Kitagawa K, Hosomi N, Nagai Y, Kagimura T, Ohtsuki T, Origasa H, Minematsu K, Uchiyama S, Nakamura M, Matsumoto M and J-STARS Investigators: Reduction in high-sensitivity C-reactive protein levels in patients with ischemic stroke by statin treatment: Hs-CRP Sub-Study in J-STARS. J Atheroscler Thromb, 2017; 24: 1039-1047

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of statin treatment for recurrent stroke according to stroke subtypes;Journal of Medicine and Life Science;2024-05-31

2. Leukoaraiosis: Epidemiology, Imaging, Risk Factors, and Management of Age-Related Cerebral White Matter Hyperintensities;Journal of Stroke;2024-05-31

3. Statins—From Fungi to Pharmacy;International Journal of Molecular Sciences;2023-12-29